CYP2C19 Polymorphisms

0.0(0)
Studied by 0 people
call kaiCall Kai
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/30

encourage image

There's no tags or description

Looks like no tags are added yet.

31 Terms

1
New cards

affected drugs of CYP2C19 Polymorphism

  • clopidogrel (antiplatelet)

  • PPIs

    • pantoprazole, omeprazole, lansoprazole, dexlansoprazole

  • Voriconazole (antifungal)

  • SSRIs

    • sertraline

    • citalopram, escitalopram

  • TCAs

    • amitrriptyline

    • imipramine, trimipramine, clomipramine

    • doxepin


2
New cards

how many alleles for CYP2C19

49 core alleles

3
New cards

CYP2C19 alleles

  • *1

  • *2, 3, 4, 5, 6, 7, 8

  • *17


  • * 1 = wild type

  • *2, 3, 4, 5, 6, 7, 8 = reduced function

  • *17 = increased expression/function


4
New cards

CYP2C19 phenotypes

  • Wild Type 1/1

  • Heterozygous *1 / (reduced func.)

  • Homozygous for reduced function

  • Heterozygous for reduced function

  • Heterozygous 1/17

  • Homozygous 17/17


  • Wild Type 1/1 = normal/extensive metabolizer

  • Heterozygous *1 / (reduced func.) = immediate metabolizer

  • Homozygous for reduced function = poor metabolizer 

  • Heterozygous for reduced function = poor metabolizer

  • Heterozygous 1/17 = rapid metabolizer

  • Homozygous 17/17 = ultrarapid metabolizer


5
New cards

CYP2C19 phenotypes: common by ethnic group

  • africans / americans → normal or ultrarapid (*1, *17)

  • east / oceanian → *1, 2, 3


6
New cards

clopidogrel: a — requiring CYP2C19 metabolism for activation

prodrug

  • rapidly absorbed in liver → 85% inactive metabolite + 15% active


7
New cards

active metabolite of clopidogrel

block P2RY21 receptor (antiplatelet effect)

8
New cards

CYP2C19 metabolism: inactive prodrug → active clopidogrel

  • increased CYP2C19 function

  • decreased CYP2C19 function


  • increased function

    • increased active clopidogrel = increased side effects (bleeding)

  • decreased function

    • decreased activity → decreased efficacy (risk for stroke, MI, thrombosis)


9
New cards
<p>A = </p><p>D = </p>

A =

D =

A = ultrarapid metabolizer (more active drug)

D = poor metabolizer (less active drug)

10
New cards
  • do not use clopidogrel with — inhibiting CYP2C19

  • alternative?


  • Omeprazole or PPIs

  • alternative = Rabeprazole or H2RAs


11
New cards

BBW for metabolism of clopidogrel by CYP2C19

effectiveness dependent on CYP2C19 and poor metabolizer have higher CV rates

12
New cards

cardiovascular indications (ACS, PCI)

  • ultrarapid or rapid, normal

  • intermediate

  • poor


  • ultrarapid or rapid and normal (17/17, 1/17, 1/1)

    • increased platelet inhibition or normal

    • label rec dosage and admin


  • intermediate (1/2, 1/3, 2/17. 3/17) and poor (2/2, 2/3, 3/3)

    • reduced platelet inhibition

    • increased risk of ADE

    • use Prasugruel, Ticagrelor


<ul><li><p>ultrarapid or rapid and normal (17/17, 1/17, 1/1)</p><ul><li><p>increased platelet inhibition or normal </p></li><li><p>label rec dosage and admin </p></li></ul></li></ul><p></p><ul><li><p>intermediate (1/2, 1/3, 2/17. 3/17) and poor (2/2, 2/3, 3/3)</p><ul><li><p>reduced platelet inhibition </p></li><li><p>increased risk of ADE</p></li><li><p>use Prasugruel, Ticagrelor </p></li></ul></li></ul><p></p>
13
New cards

neurovascular indications (stroke, TIA)

  • ultrarapid or rapid, normal

  • intermediate

  • poor


  • ultrarapid or rapid and normal (17/17, 1/17, 1/1)

    • increased active metabolite formation or normal

    • no recommendation (UM) or label rec dosage and admin (NM)


  • intermediate (1/2, 1/3, 2/17. 3/17) and poor (2/2, 2/3, 3/3)

    • reduced clopidogrel active metabolite formation

    • increased risk of ADE

    • consider alternative P2Y12 inhibitor (Ticagrelor and Ticlopidine)


<ul><li><p>ultrarapid or rapid and normal (17/17, 1/17, 1/1)</p><ul><li><p>increased active metabolite formation or normal </p></li><li><p>no recommendation (UM) or label rec dosage and admin (NM)</p></li></ul></li></ul><p></p><ul><li><p>intermediate (1/2, 1/3, 2/17. 3/17) and poor (2/2, 2/3, 3/3)</p><ul><li><p>reduced clopidogrel active metabolite formation  </p></li><li><p>increased risk of ADE</p></li><li><p>consider alternative P2Y12 inhibitor (Ticagrelor and Ticlopidine)</p></li></ul></li></ul><p></p>
14
New cards

what medication is contraindicated in pts w/ hx of stroke or TIA?

Prasugruel

15
New cards

contraindications

  • Clopidogrel

  • Prasugruel

  • Ticagrelor


  • Clopidogrel

    • hypersensitivity

    • active bleeding

  • Prasugruel

    • hypersensitivity

    • active bleeding

    • prior TIA or stroke

  • Ticagrelor

    • hypersensitivity

    • active pathological bleeding

    • hx of intracranial hemorrhage


16
New cards

comparison of different P2Y12 inhibitors

  • Clopidogrel

  • Prasugruel

  • Ticagrelor


  • Clopidogrel

    • prodrug

    • 2 step activation

    • inexpensive

  • Prasugruel

    • prodrug

    • 1 step activation

    • inexpensive

  • Ticagrelor

    • not a prodrug

    • no activation required

    • expensive


<ul><li><p>Clopidogrel </p><ul><li><p>prodrug </p></li><li><p>2 step activation </p></li><li><p>inexpensive </p></li></ul></li><li><p>Prasugruel </p><ul><li><p>prodrug </p></li><li><p>1 step activation </p></li><li><p>inexpensive </p></li></ul></li><li><p>Ticagrelor </p><ul><li><p>not a prodrug </p></li><li><p>no activation required </p></li><li><p>expensive </p></li></ul></li></ul><p></p>
17
New cards

phenoconversion

  • mismatch between genotype and predicted phenotype

  • 2C19 and 2D6 show this the most


18
New cards

causes of CYP2C19 phenoconversion

  • Inhibitors (shift to poor metabolizer phenotype):

    • SSRIs: fluvoxamine, fluoxetine

    • Antifungals: voriconazole, ketoconazole, itraconazole

    • PPIs: omeprazole, esomeprazole, lansoprazole

    • Antiplatelets: ticlopidine


  • Inducers (shift to ultrarapid phenotype):

– Rifampin


19
New cards

— and — are prescribed along with clopidogrel to minimize risk of GI bleeding

PPIs and H2RAs

20
New cards

concurrent use of omeprazole or its S isoform (esomeprazole) can

lead to significant decrease in clopidogrel efficacy resulting in treatment failure (increased risk of CV events

21
New cards

H2RAs

famotidine, cimetidine

22
New cards

omeprazole is metabolized by — and it also inhibits —

CYP2C19

23
New cards

omeprazole competes w/ clopidogrel and reduces its

conversion to the active metabolite

Patients with reduced function alleles are at an even higher risk for therapeutic failure

24
New cards

SSRI metabolism: pts w/ reduced function alleles of CYP2C19 will have

higher concentrations of sertraline, citalopram, and escitalopram, thus a

higher risk of side effects

25
New cards

SSRI side effects

  • insomnia

  • HA

  • GI and sexual dysfunction

  • arrythmias

  • QT prolongation


26
New cards

CYP2C19 recommendations for PPIs

  • UM (17/17)

  • RM (1/17)


  • UM (17/17)

    • decreased plasma concentration of PPIs

    • increase starting daily dose by 100% (divided doses)

  • RM (1/17)

    • increased risk of tx failure

    • standard daily dose

    • consider increase dose by 50-100% in Helicobacter pylori infection and erosive esophagitis


<ul><li><p>UM (17/17)</p><ul><li><p>decreased plasma concentration of PPIs </p></li><li><p>increase starting daily dose by 100% (divided doses)</p></li></ul></li><li><p>RM (1/17)</p><ul><li><p>increased risk of tx failure </p></li><li><p>standard daily dose </p></li><li><p>consider increase dose by 50-100% in Helicobacter pylori infection and erosive esophagitis </p></li></ul></li></ul><p></p>
27
New cards

CYP2C19 and Voriconazole Metabolism

  • A triazole antifungal indicated for invasive aspergillosis

  • Wide interpatient variability

  • MOA

    • Like all azole agents, inhibits CYP450 dependent cell membrane ergostrerol à ergosterol synthesis by fungi


28
New cards

CYP2C19 recommendations for Voriconazole

  • UM (17/17) or RM (1/17)

  • PM (2/2, 2/3, 3/3)


  • UM (17/17) or RM (1/17)

    • increased metabolism → therapeutic concentration small

    • alternative agent (isavuconazole, liposomal amphtercin B, posaconazole)

  • PM (2/2, 2/3, 3/3)

    • greatly reduced metabolism → high concentration

    • alternative agent (isavuconazole, liposomal amphtercin B, posaconazole)

    • if voriconazole most appropriate → adminster at lower dose w/ TDM (trough = 0.5-0.6)


<ul><li><p>UM (17/17) or RM (1/17)</p><ul><li><p>increased metabolism → therapeutic concentration small </p></li><li><p>alternative agent (isavuconazole, liposomal amphtercin B, posaconazole)</p></li></ul></li><li><p>PM (2/2, 2/3, 3/3)</p><ul><li><p>greatly reduced metabolism → high concentration </p></li><li><p>alternative agent (isavuconazole, liposomal amphtercin B, posaconazole)</p></li><li><p>if voriconazole most appropriate → adminster at lower dose w/ TDM (trough = 0.5-0.6) </p></li></ul></li></ul><p></p>
29
New cards

CYP2C19 recommendations for SSRIs

  • UM

  • RM

  • PM


  • UM

    • Sertraline = recommended starting dose

    • Citalopram/escitalopram = alternative agent not metabolized by CYP2C19

  • RM

    • Sertraline = recommended starting dose

    • Citalopram/escitalopram = recommended starting dose OR titrate or alternative agent not metabolized by CYP2C19 OR if no response

  • PM

    • 50% reduction of starting dose/titrate OR alternative agent


30
New cards

CYP2B6 recommendations for sertraline

  • IM (1/6, 1/18, 4/6, 4/18)

  • PM


  • IM

    • reduced metabolism

    • recommended starting dose

    • slower titration and lower maintance dose

    • optional

  • PM

    • greatly reduced metabolism → high concentration/side effects

    • lower starting dose, titration, 25% reduction of maintenance dose

    • optional


<ul><li><p>IM </p><ul><li><p>reduced metabolism </p></li><li><p>recommended starting dose </p></li><li><p>slower titration and lower maintance dose </p></li><li><p>optional </p></li></ul></li><li><p>PM </p><ul><li><p>greatly reduced metabolism → high concentration/side effects </p></li><li><p>lower starting dose, titration, 25% reduction of maintenance dose </p></li><li><p>optional</p></li></ul></li></ul><p></p>
31
New cards

CYP2B6 and CYP2C19 recommendations for Sertraline

  • UM/RM

  • NM

  • IM

  • PM



<p></p>